Federation Des Caisses Desjardins Du Quebec Halozyme Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $23.7 Billion
- Q3 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 8,262 shares of HALO stock, worth $578,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,262
Previous 75
10916.0%
Holding current value
$578,587
Previous $3,000
20066.67%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
664Shares Held
126MCall Options Held
599KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$810 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...